|  |  |  |
| --- | --- | --- |
| **Supplementary Table 2. Patient characteristics of the training and test sets** |  |  |
| **Characteristic** | **Training** | **Test** | ***p*** |
| Group, *n* (%) | Without OILI | 2236 (96.34) | 958 (96.38) | 0.955a |
|  | OILI | 85 (3.66) | 36 (3.62) |  |
| Sex, *n* (%) | Female | 852 (36.71) | 347 (34.91) | 0.323a |
|  | Male | 1469 (63.29) | 647 (65.09) |  |
| Age in years | Median | 57 | 56 | 0.225b |
|  | P25–P75 | 49-63 | 49-63 |  |
| Height in cm | Median | 165 | 165 | 0.124b |
|  | P25–P75 | 159-170 | 160-170 |  |
| Weight in kg | Median | 58 | 58 | 0.727b |
|  | P25–P75 | 50.5-64 | 51-64 |  |
| BMI | Median | 21 | 21.11 | 0.822b |
|  | P25–P75 | 19.38-22.86 | 19.22-23.08 |  |
| KPS score | Median | 85 | 90 | 0.215b |
|  | P25–P75 | 80-90 | 80-90 |  |
| History of hepatitis B, *n* (%) | No | 2279 (98.19) | 976 (98.19) | 0.998a |
|  | Yes | 42 (1.81) | 18 (1.81) |  |
| History of renal calculi, *n* (%) | No | 2304 (99.27) | 987 (99.3) | 0.930a |
|  | Yes | 17 (0.73) | 7 (0.7) |  |
| Comorbidities |
| Diabetes, *n* (%) | No | 2205 (95) | 935 (94.06) | 0.269a |
|  | Yes | 116 (5) | 59 (5.94) |  |
| Hypertension, *n* (%) | No | 2011 (86.64) | 857 (86.22) | 0.742a |
|  | Yes | 310 (13.36) | 137 (13.78) |  |
| Cerebral infarction, *n* (%) | No | 2294 (98.84) | 983 (98.89) | 0.888a |
|  | Yes | 27 (1.16) | 11 (1.11) |  |
| Gastritis, *n* (%) | No | 2289 (98.62) | 978 (98.39) | 0.610a |
|  | Yes | 32 (1.38) | 16 (1.61) |  |
| Duodenal ulcer, *n* (%) | No | 2311 (99.57) | 991 (99.7) | 0.809c |
|  | Yes | 10 (0.43) | 3 (0.3) |  |
| Chemotherapy regimen, *n* (%) | FOLFOX | 1360 (58.6) | 606 (60.97) | 0.872a |
|  | XELOX | 477 (20.55) | 188 (18.91) |  |
|  | GEMOX | 31 (1.34) | 14 (1.41) |  |
|  | SOX | 254 (10.94) | 107 (10.76) |  |
|  | OXA & raltitrexed | 71 (3.06) | 29 (2.92) |  |
|  | OXA | 27 (1.16) | 13 (1.31) |  |
|  | Others | 101 (4.35) | 37 (3.72) |  |
| Chemotherapy cycles | Median | 3 | 3 | 0.798b |
|  | P25–P75 | 2-5 | 2-5 |  |
| Single dose of OXA in mg | Median | 150 | 150 | 0.850b |
|  | P25–P75 | 120-180 | 125-170 |  |
| Total dose of OXA in mg | Median | 450 | 440 | 0.997b |
|  | P25–P75 | 230-750 | 230-750 |  |
| Prophylactic drugs |
| 5-HT3 receptor antagonists, *n* (%) | No | 153 (6.59) | 72 (7.24) | 0.494a |
|  | Yes | 2168 (93.41) | 922 (92.76) |  |
| Proton pump inhibitors, *n* (%) | No | 944 (40.67) | 417 (41.95) | 0.493a |
|  | Yes | 1377 (59.33) | 577 (58.05) |  |
| Liver protective drugs, *n* (%) | No | 1793 (77.25) | 789 (79.38) | 0.177a |
|  | Yes | 528 (22.75) | 205 (20.62) |  |
| Glucocorticoid drugs, *n* (%) | No | 1922 (82.81) | 827 (83.2) | 0.784a |
|  | Yes | 399 (17.19) | 167 (16.8) |  |
| Antihistamine drugs, *n* (%) | No | 1944 (83.76) | 813 (81.79) | 0.166a |
| 　 | Yes | 377 (16.24) | 181 (18.21) | 　 |
| aPearson's chi-square test; bMann-Whitney *U* test; cContinuity Correction. BMI, body mass index; KPS, Karnofsky performance status, OXA, oxaliplatin. |